Lack of Hypophagia in CB1 Null Mice is Associated to Decreased Hypothalamic POMC and CART Expression by Lage Fernández, Ricardo et al.
Received: August 17, 2014; Revised: December 19, 2014; Accepted: January 22, 2015
© The Author 2015. Published by Oxford University Press on behalf of CINP.




This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, 
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
brief report
Lack of Hypophagia in CB1 Null Mice is Associated 
to Decreased Hypothalamic POMC and CART 
Expression
Ricardo Lage, PhD; Claudia Parisi, PhD; Patricia Seoane-Collazo, BSc; 
Johan Fernø, PhD; Roberta Mazza, PhD; Fátima Bosch, PhD; Luisa M. Seoane, 
PhD; Ruben Nogueiras, PhD; Carlos Diéguez, PhD, MD; Carmelo Quarta, PhD; 
Miguel López, PhD
Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 
Santiago de Compostela, 15782, Spain (Drs Lage, Parisi, Seoane-Collazo, Fernø, Nogueiras, Diéguez, and 
López); CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain (Drs Lage, Seoane-Collazo, 
Seoane, Nogueiras, Diéguez, and López); Center of Animal Biotechnology and Gene Therapy and Department 
of Biochemistry and Molecular Biology, School of Veterinary Medicine, Universitat Autònoma Barcelona, 
Bellaterra, 08193, Spain (Drs Lage and Bosch); Endocrinology Unit and Center for Applied Biomedical Research, 
Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy (Drs Parisi, Mazza, 
and Quarta); Department of Clinical Science, K. G. Jebsen Center for Diabetes Research, University of Bergen, 
Bergen, N-5020, Norway (Dr Fernø); Grupo Fisiopatología Endocrina, Complexo Hospitalario Universitario de 
Santiago (CHUS/SERGAS), Santiago de Compostela, 15706, Spain (Dr Seoane).
Correspondence: Ricardo Lage, PhD, Department of Physiology, NeurObesity Group, CIMUS, University of Santiago de Compostela-Instituto de 
Investigación Sanitaria, Santiago de Compostela, 15782, Spain (ricardo.lage@usc.es).
Miguel López, PhD, Department of Physiology, NeurObesity Group, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, 
Santiago de Compostela, 15782, Spain (m.lopez@usc.es).
Abstract
Background: Cumulative data indicate that the endocannabinoid system plays a major role in feeding behavior and energy 
balance. Genetic silencing of cannabinoid receptor type 1 (CB1) reduces body weight gain, independently of food intake.
Methods: In this work, we investigated whether the hypothalamic neuropeptide expression pattern supports the absence of 
the anorexigenic response observed under constitutive CB1 ablation, by using neuronal CB1 conditional null mice (CamK-
CB1-KO) and whole body CB1 null mice (CB1-KO).
Results: Our data showed that both CB1 null models display a marked decrease in proopiomelanocortin (POMC) and cocaine-
amphetamine-regulated transcript (CART) expression in the arcuate nucleus of the hypothalamus (ARC).
Conclusions: This evidence suggests that a lack of hypophagia is associated with the suppression of ARC anorexigenic 
neuropeptides and that behavioral changes in food intake (or lack thereof) after constitutive CB1 ablation are likely mediated 
by impaired melanocortin and CART signaling in the hypothalamus.
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Introduction
The endocannabinoid system (ECS), consists of endogenous 
cannabinoids, the enzymatic machinery involved in their syn-
thesis and degradation, and the G-protein-coupled cannabi-
noid receptors type 1 and 2 (CB1 and CB2; Quarta et al., 2011). 
This system has emerged as a major regulatory mechanism 
of several physiological and pathophysiological processes, 
including feeding behavior and energy balance, where ECS acti-
vation promotes energy storage (Bermudez-Silva et  al., 2010, 
2012; Quarta et  al., 2010). Central administration of cannabi-
noids increases food intake through CB1 activation (Jamshidi 
and Taylor, 2001; Verty et al., 2005). It is also known that feed-
ing suppression induced by a cannabinoid receptor blockade 
has a major peripheral component through the involvement 
of either peripheral nerve terminals, a direct participation of 
sympathetic nervous system, ghrelin, or leptin (Alen et  al., 
2013; Silvestri and Di Marzo, 2013). Moreover, rodents with diet-
induced or genetic obesity show increased endocannabinoid 
hypothalamic levels (Quarta et  al., 2011). Conversely, genetic 
or pharmacological CB1 silencing (Verty et  al., 2009; Quarta 
et al., 2010; Rorato et al., 2013) supresses food intake in lean 
and obese starved animals (Quarta et al., 2011). However, stud-
ies have shown that CB1 blockade decreases fat mass and body 
weight gain independently of changes in food intake, mainly 
through increased sympathetic outflow, mitochondrial biogen-
esis, and heat production, as well as fatty acid mobilization 
and oxidation (Jbilo et al., 2005; Nogueiras et al., 2008; Quarta 
et  al., 2010). As a result, CB1 blockade ameliorates obesity-
related metabolic disorders (Cota et  al., 2003; Ravinet Trillou 
et al., 2004; Quarta et al., 2011).
The endocannabinoid system is thought to regulate food 
intake, essentially by affecting eating motivation through the 
mesolimbic pathway (Di Marzo et al., 2009) and the hypothal-
amus (Cota et  al., 2003; Verty et  al., 2005, 2009; Rorato et  al., 
2013). Pharmacological modulation of the ECS regulates neu-
ronal activity (in parallel to feeding behavior) in the paraven-
tricular (PVH), ventromedial, and arcuate (ARC) nuclei of the 
hypothalamus, as well as in the dorsomedial nucleus and lat-
eral hypothalamic area (Verty et al., 2009; Soria-Gomez et al., 
2014). Also, the endogenous cannabinoid ligand anandamide 
(arachidonylethanolamide) increases food intake through 
CB1 receptor activation when infused into the ventrome-
dial nculei of the hypothalamus (Jamshidi and Taylor, 2001). 
Within the hypothalamus, the CB1 receptor has been shown 
to colocalize with corticotropin-releasing hormone (CRH) and 
cocaine-amphetamine-regulated transcript (CART) neurons 
in the PVH (Cota et al., 2003), suggesting a direct influence of 
endocannabinoids on hypothalamic neuropeptide expression. 
Accordingly, different studies have shown that the decrease 
in food intake induced by CB1 receptor antagonism is associ-
ated with increased CRH (Verty et al., 2009; Rorato et al., 2013), 
α-melanocyte-stimulating hormone (Verty et  al., 2009), and 
CART (Verty et al., 2009; Rorato et al., 2013) expression, as well 
as decreased neuropeptide Y (NPY) levels (Verty et  al., 2009; 
Rorato et al., 2013).
Interestingly, it has been demonstrated that chronic pharma-
cological treatment with CB1 receptor antagonists renders ani-
mals tolerant to their anorectic action (Quarta et al., 2010; Rorato 
et al., 2013). Thus, chronic CB1 receptor antagonism might lead 
to neuronal and neuropeptide changes different from those 
observed after acute treatments in rats (Rorato et  al., 2013). 
Accordingly, previous data have shown no changes in feeding 
behavior in adult conditional mutants lacking CB1 receptor 
neuronal expression (CamK-CB1-KO) or in total CB1 receptor 
knockout (CB1-KO) adult mice (Quarta et al., 2010). In contrast, 
food intake is reduced in young CB1-KO mice (Cota et al., 2003). 
Here, we analyzed the role of the CB1 receptor on feeding behav-
ior and hypothalamic neuropeptides, using CamK-CB1-KO and 
CB1-KO mutant adult male mice fed a standard (SD) or high 
fat diet (HFD). Our data suggest that the lack of decreased food 
intake in both models, which are in contrast to those observed 
after CB1 receptor acute antagonism (Rorato et al., 2013), further 
highlights the relevance of neuronal plasticity in energy homeo-
stasis. These data provide new clues for understanding how the 
cannabinoid system is involved in the regulation of food intake, 
which should aid further developments of new CB1 antagonists.
Methods
Animals
We used adult (8 weeks) male CB1-KO mice (Cota et al., 2003; 
Ravinet Trillou et  al., 2004) and CaMK-CB1-KO mice and their 
wildtype (WT) littermates. In CaMK-CB1-KO mice, the CB1 
receptor was deleted in forebrain neurons expressing the Ca2+/
calmodulin dependent kinase IIa, while CB1 expression is main-
tained in cortical GABAergic interneurons and in cerebellar neu-
rons (Marsicano et al., 2003). Mutant animals were in a mixed 
genetic background, with a predominant C57BL/6N contribution 
(seven backcrosses). The experiments were performed in agree-
ment with the International Law on Animal Experimentation 
and were approved by the University of Bologna and USC Local 
Ethical Committee and the USC Ethical Committee (Project ID 
15010/14/006). We used 6–10 animals per group. Animals were 
fed either a SD containing 12.3 KJ/g (11% fat, 19% protein, 70% 
carbohydrate) or a HFD having 18.9 KJ/g (40% fat, 15% protein, 
45% carbohydrate; both diets from Dottor Piccioni Lab).
Peripheral Treatment with CB1 Antagonist
C57BL6 mice were treated intraperitoneally (i.p.; 4 hours) with 
either the CB1 antagonist AM281 (Tocris Bioscience; 3mg/Kg) or 
vehicle (dimethyl sulfoxide) after overnight fasting.
 Serum Analyses
Serum leptin concentrations were determined using a Mouse 
Leptin ELISA kit EZML-82K (Millipore). Ghrelin concentrations 
were measured using a Rat/Mouse Ghrelin (Total) ELISA kit 
EZRGRT-91K (Millipore) and peptide YY (PYY3-36) concentra-
tions were determined using a Peptide YY (3-36; Rat, Mouse, 
Porcine, Canine) EIA Kit EK-059-04 (Phoenix Pharmaceuticals, 
Inc.).
In Situ Hybridization
Specific oligonucleotides for agouti-related peptide (AgRP), 
CART, CRH, NPY, and proopiomelanocortin (POMC) detec-
tion were used (Supplementary Table S1). These probes were 
3’-end labeled with 35S-α-dATP using terminal deoxynucleoti-
dyl transferase (Amersham Biosciences). In situ hybridizations 
were performed as previously published (Lopez et  al., 2008, 
2010; Lage et al., 2010; Martinez de Morentin et al., 2014). The 
slides from all experimental groups from the same experi-
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were exposed to the same autoradiographic film. All sec-
tions (16  μm) were scanned and the specific hybridization 
signal was quantified by densitometry (ImageJ 1.33, National 
Institutes of Health). The optical density of the hybridization 
signal was determined and subsequently corrected by the 
optical density of its adjacent background. We used 6–10 ani-
mals/group and 16–20 sections/animal (4–5 slides with four 
sections/slide).
Statistical Analysis
Data are expressed as mean ± standard error of the mean. 
Statistical significance was determined by student’s t-test. 
A p-value < 0.05 was considered significant.
Results
Food Intake, Body Weight, and Hormonal Plasma 
Levels in Adult CB1-KO Mice
When compared to WT littermates fed the SD (Figure 1A) or HFD 
(Figure 1B), CB1-KO mice showed a sustained decrease in body 
weight. Still, no differences in food intake were found between 
CB1-KO mice and their respective WT littermates during this 
period on either the SD (Figure 1C) or HFD (Figure 1D). The HFD 
did not impact circulating levels of ghrelin or PYY3-36, althought 
differences in ghrelin levels become significant when both gen-
otypes are compared on a HFD. In keeping with the body weight 
data, a HFD did not induce a further increase in leptin levels in 
CB1-KO mice (Supplementary Table S2).
Figure 1. Food intake, body weight, and hypothalamic neuropeptide expression in adult whole body CB1 null mice (CB1-KO) mice. (A and B) Body weight gain and (C 
and D) cumulative food intake between 8–20 weeks in CB1-KO mice under either a standard diet (SD; A and C) or high-fat diet (HFD; B and D). (E–H) Representative in 
situ hybridization autoradiographic images (left panels) and neuroptide mRNA levels (right panels) of anorexigenic (E and F) and orexigenic (G and H) neuropeptides, in 
CB1-KO mice under SD (E and G) and HFD (F and H). AgRP, agouti-related peptide; ARC, arcuate nucleus of the hypothalamus; CART, cocaine-amphetamine-regulated 
transcript; CRH, corticotropin-releasing hormone; DMH, dorsomedial nucleus of the hypothalamus; LHA, lateral hypothalamic area; NPY, neuropeptide Y; POMC, 
proopiomelanocortin; PVH, paraventricular nuclei of the hypothalamus. Data are expressed as mean ± standard error of the mean; n = 7–10 animals per experimental 
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CB1 Antagonism in Mice Fed HFD
Mice fed a HFD acutely (4 hours) and i.p. treated with the 
CB1 antagonist AM281 diplayed significantly hypophagia 
(Supplementary Figure S1A) with concominant increases in 
the expression of CART and POMC in the ARC (Supplementary 
Figure S1B).
Hypothalamic Neuropeptide Expression in CB1-KO
A significant decrease in the mRNA levels of CART and POMC 
was detected in the ARC of CB1-KO mice, both under SD (WT 
and KO n = 7; CART: p = 0.02; POMC: p = 0.03; Figure 1E) and HFD 
(WT and KO n = 10; CART: p = 0.008; POMC: p = 0.03; Figure 1F). 
CB1-KO mice showed a increase in AgRP mRNA levels, regard-
less of the diet (p  =  0.029 in HFD; Figure  1G and 1H), and a 
significant increase in NPY mRNA in SD (p  =  0.027 in HFD; 
Figure 1G).
Food Intake, Body Weight, and Hormonal Plasma 
Levels in Adult CaMK-CB1-KO Mice
When compared to WT littermates fed a SD (Figure 2A) or HFD 
(Figure 2B), CaMK-CB1-KO mice showed a sustained, lower body 
weight. Similar to CB1-KO mice, no differences in food intake 
were found between CaMK-CB1-KO mice and their respective 
Figure 2. Food intake, body weight, and hypothalamic neuropeptide expression in adult neuronal CB1 conditional null mice (CamK-CB1-KO) mice. (A and B) Body 
weight gain and (C and D) cumulative food intake between 8–20 weeks in CaMK-CB1-KO mice under either a standard diet (SD; A and C) or high-fat diet (HFD; B and D). 
(E–H) Representative in situ hybridization autoradiographic images (left panels) and neuroptide mRNA levels (right panels) of anorexigenic (E and F) and orexigenic (G 
and H) neuropeptides, in CaMK-CB1-KO mice under SD (E and G) and HFD (F and H). ARC, arcuate nucleus of the hypothalamus; LHA, lateral hypothalamic area; DMH, 
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WT littermates during this period under either SD (Figure 2C) or 
HFD (Figure 2D). HFD did not impact PYY3-36 circulating levels 
but induced a non-significant trend towards decreased ghre-
lin levels (p = 0.09). In keeping with the body weight data, HFD 
did not induce increased leptin levels in CaMK-CB1-KO mice 
(Supplementary Table S2).
Hypothalamic Neuropeptide Expression in CaMK-
CB1-KO Mice
A significant decrease in CART and POMC mRNA levels was 
detected in the ARC of CaMK-CB1-KO mice as compared to 
their WT littermates fed either a SD (WT n = 7; KO n = 6; CART: 
p = 0.02; POMC: p = 0.04; Figure 2E) or HFD (WT and KO n = 8; 
CART: p = 0.03; POMC: p = 0.03; Figure 2F). These changes were 
independent of the diet. No differences were detected in AgRP or 
NPY mRNA expression in this animal model when subjected to 
either SD (Figure 2G) or HFD (Figure 2H).
Discussion
Despite the recognition of the hypothalamus as a key struc-
ture involved in the regulation of feeding by cannabinoids, the 
hypothalamic mechanisms mediating this effect are poorly 
understood. Here, we analyzed hypothalamic neuropeptide 
expression in CaMK-CB1-KO and CB1-KO adult mice, aiming 
at clarifying the absence of an anorectic response associated 
with a prolonged ECS blockade. Our data reveal a significantly 
decreased expression of anorectic neuropeptides, namely POMC 
and CART, in both CB1-genetic models, an effect that was inde-
pendent of the diet. These molecular changes suggest that the 
lack of hypophagia is mediated by a compensatory mechanism, 
leading to decreased expression of anorectic signals within 
the hypothalamus. Thus, hypothalamic neuropeptide regula-
tion would be an adaptative response, secondary to metabolic 
changes, as a strategy to find and/or keep a new energy balance 
while avoiding depletion of energetic stores.
As previously reported, our data show a lower body weight 
gain in both adult CaMK-CB1-KO and CB1-KO mice compared 
with their respective WT controls, with a more pronounced phe-
notype in CB1-KO mice (Cota et  al., 2003; Quarta et  al., 2010). 
We also observed no effect of CB1 genetic deletion on feeding 
behavior in adult mice (Cota et al., 2003; Quarta et al., 2010), sug-
gesting that an adaptive tolerance to early hypophagia takes 
place (Quarta et  al., 2010). This tolerance to anorectic stimuli 
was previously reported in long-term pharmacological studies 
with CB1 receptor antagonists (Verty et al., 2009; Rorato et al., 
2013).
The interaction between CB1 and the melanocortin system 
in regulating feeding is unclear (Colombo et al., 1998). Our data 
showed a diet-independent significant decrease in POMC mRNA 
levels in both CaMK-CB1-KO and CB1-KO mice compared to their 
respective WT littermates. Although some studies have reported 
no changes in POMC expression when administering the CB1 
antagonist rimonabant (Verty et al., 2004; Sinnayah et al., 2008), 
these molecular analyses were conducted after long-term 
rimonabant treatment when no more differences in eating 
behavior were found, suggesting that tolerance was reached 
(Rorato et al., 2013). Conversely, in relation to the modulation of 
hypothalamic neuropeptides under acute CB1 receptor antag-
onism, it has recently been demonstrated that a significant 
increase of α-melanocyte-stimulating hormone, causes a molec-
ular change that is in agreement with the anorexia observed 
(Rorato et al., 2013). Thus, our data suggest that under prolonged 
CB1 silencing, the significant decrease in POMC mRNA may pre-
vent the anorectic response observed in young animals (Verty 
et al., 2009). Our data also reveal that, in parallel to the decrease 
in POMC levels, there is a significant decrease in mRNA expres-
sion levels of the anorexigenic precursor CART within the ARC 
of both CaMK-CB1-KO and CB1-KO mice. Similarity to POMC, 
CART suppression was observed irrespective of the type of diet. 
Decreased CART expression has been implicated in the orexi-
genic response to the CB1 agonist anandamide (Cota et al., 2003). 
Accordingly, acute CB1 antagonism increases CART levels in the 
ARC (Osei-Hyiaman et  al., 2005), and a pharmacological CB1 
blockade is unable to suppress food intake in CART-deficient 
mice (Verty et  al., 2009), suggesting a critical role for CART in 
mediating the action of the ECS on food intake. Thus, the sup-
pression in CART may contribute to the lack of hypophagia that 
characterizes these two animal models of genetic CB1 ablation.
We also detected a marked rise in ARC orexigenic neuro-
peptides, namely AgRP or NPY, in CB1-KO mice. Cumulative 
studies report conflicting results concerning the interaction 
between endocannabinoids and NPY. For example, NPY is 
overexpressed or suppressed in response to anandamide or 
rimonabant, respectively (Osei-Hyiaman et al., 2005). However, 
NPY-deficient mice maintain an intact anorectic response when 
treated acutely with a CB1 receptor antagonist, suggesting that 
the NPY system plays a minor role in determining the observed 
anorexia. Notably, the two CB1 null models used in this study 
display a common loss of anorexigenic neuropeptide expres-
sion, independently of ARC orexigenic neuropeptides, suggest-
ing that the changes are mediated by central CB1 receptors. In 
this regard, it is interesting to note that ghrelin showed a non-
significant tendency towards increased levels in total CB1-KO 
mice when compared with CaMK-CB1-KO mice. This difference 
became significant when both genotypes were fed a HFD. Given 
that AgRP and NPY are hypothalamic targets of ghrelin (Lopez 
et  al., 2008; Lage et  al., 2010), it is possible that differences in 
basal ghrelin between genotypes account for the discrepancy in 
AgRP and NPY expression, a hypothesis that will require further 
investigation.
Previous studies showed increased PVH neuronal activ-
ity and CRH overexpression under acute pharmacological CB1 
antagonism (Verty et al., 2009; Rorato et al., 2013). The anorectic 
role of CRH is widely established, and cumulative data indicate 
that CRH overexpression could underlie the anorectic effect of 
acute CB1 antagonist administration (Verty et al., 2009; Rorato 
et al., 2013). Consistently, hypophagic young CB1-KO mice show 
increased CRH mRNA levels, suggesting that CB1 receptor acti-
vation inhibits CRH expression (Cota et al., 2003; Osei-Hyiaman 
et al., 2005; Verty et al., 2005, 2009; Rorato et al., 2013). Consistent 
with the absence of an anorexigenic response in our animals, 
we failed to observe any substantial change in PVH or CRH 
expression. Thus, the absence of CRH upregulation, alongside 
decreased POMC and CART expression, may also contribute to 
failed hypophagia in adult mice.
In summary, our data indicate that food intake in adult mice 
under constitutive CB1 ablation is associated with a failure in 
the activation of anorexigenic signals in ARC neurons, such as 
POMC and CART, suggesting an adaptative response under sus-
tained negative energy balance that may overrule early anorectic 
responses. These data identify impaired melanocortin and CART 
signaling in the hypothalamus as possible mediators of the 
resistance to hypophagia developed after long-term CB1 abla-
tion. The similarities of the changes exhibited by both models of 
CB1-ablation clearly indicate that all the changes here reported 
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SUPPLEMENTAL FIGURE S1. Food intake and hypothalamic 
neuropeptide expression after acute treatment with the CB1 
antagonist AM281. (A) Food intake and (B) CART and POMC 
mRNA levels in the arcuate nucleus of the hypothalamus (ARC) 
of rats IP-treated with vehicle or the CB1 antagonist AM281. Data 
are expressed as mean ± SEM; n=6-8 animals per experimental 
group. * and ** P<0.05 and 0.01 vs. vehicle.
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